FPA150 in Patients With Advanced Solid Tumors (FPA150-001 Trial)
Palo Alto (17 mi)Age: 18+
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase < 1
Waitlist Available
Sponsor: Five Prime Therapeutics, Inc.
No Placebo Group
Breakthrough Therapy
Trial Summary
What is the purpose of this trial?This is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or in combination with pembrolizumab an anti-PD1 antibody in patients with advanced solid tumors. The Phase 1a, open-label, cohort will identify a recommended dose of FPA150 to use for Phase 1a Combination (FPA150 and Pembrolizumab) Safety Lead-in and for Phase 1b monotherapy cohorts.
Eligibility Criteria
Treatment Details
1Treatment groups
Experimental Treatment
Group I: Phase 1a dose escalation/1b dose expansionExperimental Treatment2 Interventions
The study consists of Phase 1a dose escalation, Phase 1a dose exploration, Phase 1a combination safety-lead-in and Phase 1b dose expansion
Find a clinic near you
Research locations nearbySelect from list below to view details:
The University of Texas MD Anderson Cancer CenterHouston, TX
Stephenson Cancer CenterOklahoma City, OK
Sarah Cannon Research InstituteNashville, TN
Honor HealthScottsdale, AZ
More Trial Locations
Loading ...
Who is running the clinical trial?
Five Prime Therapeutics, Inc.Lead Sponsor